Photo taken from Dana-Farber News/X
Jan 28, 2024, 18:44
Interim phase 1 results show HPN328 is well tolerated and clinically active for neuroendocrine carcinomas – Dana-Farber News
Dana-Farber News recently shared a post on their X/Twitter page:
“ASCO GU24: Interim phase 1 results show HPN328, a T-cell engager, is well tolerated and clinically active for patients across a wide range of neuroendocrine carcinomas. Dana-Farber Cancer Institute’s Misha Beltran explains more here.”
Source: Dana-Farber News/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19